Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

30.55 -0.67 (-2.16%)
Streaming Delayed Price Updated: 10:36 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace
News headline image
Is Beam Therapeutics Stock a Buy Now? ↗
It has plenty of money, but it'll be facing plenty of competition, too. 
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
These stocks could grow much larger over the next few years. 
Via The Motley Fool
News headline image
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks ↗
You might not get a better chance to invest in these disruptive companies. 
Via The Motley Fool
News headline image
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. 
Via Benzinga
News headline image
Beam Therapeutics: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
News headline image
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗
These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. 
Via The Motley Fool
News headline image
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? ↗
Beam Therapeutics' pipeline will look slimmer going forward. 
Via The Motley Fool
News headline image
What's Going On With Beam Therapeutics Stock Thursday? ↗
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading lower Thursday. 
Via Benzinga
News headline image
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On ↗
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
News headline image
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today ↗
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology. 
Via The Motley Fool
News headline image
Verve Stock Soars On $250 Million Eli Lilly Deal ↗
Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs. 
Via Investor's Business Daily
News headline image
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
News headline image
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? ↗
Some of the strategic shifts proposed by management are for the better. 
Via The Motley Fool
News headline image
Why Beam Therapeutics Stock Is Getting Bought Today ↗
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's  
Via Benzinga
News headline image
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender ↗
 
Via Benzinga
Topics Earnings
News headline image
5 Reasons Beam Therapeutics Remains a Risky Stock ↗
Shares of the gene-editing biotech might not have hit rock bottom yet. 
Via The Motley Fool
News headline image
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
From Beam Therapeutics
Via GlobeNewswire
News headline image
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Beam Therapeutics Stock: Bear vs. Bull ↗
This biotech has a few factors in its corner, but it also faces a difficult path. 
Via The Motley Fool
News headline image
Investors Unpack Home Sales Data Ahead Of Fed Speech ↗
Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell. 
Via Talk Markets
Topics Economy
News headline image
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
From Beam Therapeutics
Via GlobeNewswire
News headline image
3 Gene Editing Stocks to Generate Super-Charged Gains ↗
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
News headline image
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid ↗
Both are in a race against time to commercialize a medicine before cash runs out. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.